GABA Inhibitors
1 drugsAbout GABA
Gamma-aminobutyric acid (GABA) is a primary inhibitory neurotransmitter in the central nervous system, modulating neuronal excitability and various physiological processes.
GABA receptors are therapeutic targets for conditions involving neuronal overexcitation. Currently, there is no genetic evidence directly linking GABA to specific diseases.
GABA is targeted by one FDA-approved drug, QSYMIA, a small molecule used in metabolic disease. VIVUS LLC is the sole company with an approved GABA-targeting drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy Volunteers with only 1 trials.
Top Drugs
VIVUS LLC is the only company with an approved drug targeting GABA.
Low competition suggests a potential market opportunity, but also indicates possible challenges in target validation.
Drug Modality Landscape
Modalities
Routes of Administration
GABA is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could offer differentiation and novel therapeutic approaches.
Clinical Trials 33 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 10 | 1 | 1 | 91% |
| Phase 2 | 9 | 5 | 2 | 2 | 71% |
| Phase 3 | 3 | 2 | 0 | 1 | 100% |
| Phase 4 | 9 | 6 | 1 | 2 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2004 - 2012)
The first and only drug approval for GABA was QSYMIA in 2012.
The lack of recent approvals suggests either saturation or challenges in developing GABA-targeting drugs, requiring careful evaluation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting GABA.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities